| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/05/2006 | US20060223829 such as 1-Phenyl-4-(m-tolylsulfonyl)piperazine, used in the treatment of type-2 diabetes, osteoporosis, hypertension, ocular disorders, cognitive disorders, the metabolic syndrome and other metabolic disorders |
| 10/05/2006 | US20060223828 Substituted chroman derivatives |
| 10/05/2006 | US20060223827 Bioreductively activated stilbene prodrugs |
| 10/05/2006 | US20060223826 Indole derivatives as somatostatin agonists or antagonists |
| 10/05/2006 | US20060223825 Piperazinyl substituted cyclohexane-1,4-diamines |
| 10/05/2006 | US20060223824 Serotonergic agents |
| 10/05/2006 | US20060223823 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| 10/05/2006 | US20060223822 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| 10/05/2006 | US20060223821 Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| 10/05/2006 | US20060223820 Crystalline aripiprazole salts and processes for preparation and purification thereof |
| 10/05/2006 | US20060223819 Quinoline Derivatives as NK-3 Antagonists |
| 10/05/2006 | US20060223818 N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-piperazin-1-ylmethyl-benzamide methanesulfonate; antiproliferative agent |
| 10/05/2006 | US20060223817 Crystalline imatinib base and production process therefor |
| 10/05/2006 | US20060223816 Imatinib mesylate alpha form and production process therefor |
| 10/05/2006 | US20060223815 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use |
| 10/05/2006 | US20060223814 Nk-2 antagonist basic linear compounds and formulations containing them |
| 10/05/2006 | US20060223813 2-carboxamide piperazine's such as 4-hexyl-1-(thiophene-2-sulfonyl)-piperazine-2-carboxylic acid (1-ethyl-2-pyridinyl-3-yl-1H-benzoimidazol-5-yl)-amide), are potent follicle stimulating hormone receptor agonists, useful for treatment of infertility in mammals |
| 10/05/2006 | US20060223812 Treating neurodegenerative conditions |
| 10/05/2006 | US20060223811 Triglycerine depressant composition |
| 10/05/2006 | US20060223810 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid [2-(6-methoxy-quinolin-4-yl)-4,5,6,7-tetrahydro-2H-indazol-5-yl]-amide |
| 10/05/2006 | US20060223809 Thieno [2,3,-d]pyridazin-4(5H)-ones; modulation of autoimmune diseases with T-cell antiproliferatives; antiinflammatory; organ transplant rejection; AIDS; chronic obstructive pulmonary disease (COPD); asthma |
| 10/05/2006 | US20060223808 Spirocyclic thrombin receptor antagonists |
| 10/05/2006 | US20060223807 Therapeutic methods for type I diabetes |
| 10/05/2006 | US20060223806 Microbicidal composition based on formaldehyde donor compounds and antioxidants |
| 10/05/2006 | US20060223805 Arylalklcarbamate derivatives, preparation method thereof and use of same in therapeutics |
| 10/05/2006 | US20060223804 NK1 antagonists |
| 10/05/2006 | US20060223803 Process for resolving aimines that are useful for the treatment of disorders associated with insulin resistance syndrome |
| 10/05/2006 | US20060223802 Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics |
| 10/05/2006 | US20060223801 Pyrrol derivatives with antibacterial activity |
| 10/05/2006 | US20060223800 Pyrazolopyridines and pyrazolopyridazines adn antidiabetics |
| 10/05/2006 | US20060223799 e.g. Ethyl 1-(4-bromophenyl)-1,4-dihydropyrrolo[2,3-d]imidazole-5-carboxylate; inhibitors of the c-Kit proto-oncogene (KIT, CD-117, stem cell factor receptor, mast cell growth factor receptor); antiproliferative agent; breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, thyroid carcinoma |
| 10/05/2006 | US20060223798 Tetrahydrothiopyrano pyrazole cannabinoid modulators |
| 10/05/2006 | US20060223797 Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors |
| 10/05/2006 | US20060223796 Novel compounds for use in weight loss and appetite suppression in humans |
| 10/05/2006 | US20060223795 Novel diazabicyclononene derivatives |
| 10/05/2006 | US20060223794 Novel olanzapine forms and related methods of treatment |
| 10/05/2006 | US20060223793 Use of dopamine d3 receptor ligands for the production of drugs for treating renal function disorders |
| 10/05/2006 | US20060223792 Phenyl and pyridyl LTA4H modulators |
| 10/05/2006 | US20060223791 O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof |
| 10/05/2006 | US20060223790 Modulation of Microglial by Nicotinic Medications |
| 10/05/2006 | US20060223789 Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates |
| 10/05/2006 | US20060223788 Analgesic composition for topical use |
| 10/05/2006 | US20060223787 time release of 4-aminosalicylic acid and/or 5-aminosalicylic acid in the interstines by administering 4,4'-azo-bis salicylic acid and/or salts, which exhibits a delay in release that is dependent on surrounding pH; treatment of Crohn's disease and ulcerative colitis; prodrugs |
| 10/05/2006 | US20060223786 Transdermal pain control method and device |
| 10/05/2006 | US20060223785 Andrographolide derivatives to treat viral infections |
| 10/05/2006 | US20060223784 Method and compositions for temporarily incapacitating subjects |
| 10/05/2006 | US20060223783 3,4-Disubstituted coumarin and quinolone compounds |
| 10/05/2006 | US20060223782 2-Methylene-19-nor-(23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone |
| 10/05/2006 | US20060223781 Process for induction of intramolecular migration of sulfates, phosphates, and other oxyanions |
| 10/05/2006 | US20060223780 Method for administration of capecitabine |
| 10/05/2006 | US20060223779 Method of screening for inhibitors of human Fatty Acid-CoA Ligase 4 |
| 10/05/2006 | US20060223776 Crosslinking compound releasing drug in acidity environment; for use as vaccines or therapeutic agents |
| 10/05/2006 | US20060223770 IRNA agents targeting VEGF |
| 10/05/2006 | US20060223767 Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene therapy |
| 10/05/2006 | US20060223766 4'-keto derivative; treating N-Trifluoroacetyldaunorubicin with dimethylsulfoxide activated by different acylating agents, then with a strong tertiary amine base; fewer steps and protective groups; stereospecific and increased selectivity |
| 10/05/2006 | US20060223765 Method for inhibiting and/or treating vaginal infection |
| 10/05/2006 | US20060223764 Classes of compounds that interact with gpcrs |
| 10/05/2006 | US20060223763 C-glycoside compounds for stimulating the synthesis of glycosaminoglycans |
| 10/05/2006 | US20060223762 Treatment of migraine |
| 10/05/2006 | US20060223761 Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| 10/05/2006 | US20060223760 Compositions and methods for treatment of cancer |
| 10/05/2006 | US20060223758 Treating treating angiogenic disease by administering therapeutically effective amount of compounds of the invention, for example, {(3R, 4S, 5S, 6R)-5-Methoxy-4-[(2R, 3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-butyric acid methyl ester; stability |
| 10/05/2006 | US20060223750 Agents and methods for enhancing photodynamic therapy |
| 10/05/2006 | US20060223746 Injecting an alpha v beta 3 and/or alpha v beta 5 inhibitor, sufficient to inhibit or reduce angiogenesis or neovascularization in the treated eye, into the sclera layer of the eye; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid |
| 10/05/2006 | US20060223745 Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof |
| 10/05/2006 | US20060223741 of neuropathic pain comprising administering angiotensin II receptor 2 (AT2 receptor) antagonists such as 2-(Diphenylacetyl)-5-benzyloxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid |
| 10/05/2006 | US20060223740 Absorption enhancers such as e.g. bht, bha or propyl gallate |
| 10/05/2006 | US20060223180 Methods to mobilize progenitor/stem cells |
| 10/05/2006 | US20060223121 Contacting biological sample of urine, cerebrospinal fluid or serum with a peptide and complexing with a monoclonal antibody ligand; detecting an immunogenic peptide having calgranulin B protein activity; Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis; rheumatoid arthritis |
| 10/05/2006 | US20060223119 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| 10/05/2006 | US20060223003 Optical recording medium and dye |
| 10/05/2006 | US20060222756 Medical devices, drug coatings and methods of maintaining the drug coatings thereon |
| 10/05/2006 | US20060222718 Aqueous pharmaceutical solution comprising oxymetazoline and/or xylometazoline |
| 10/05/2006 | US20060222716 Colloidal solid lipid vehicle for pharmaceutical use |
| 10/05/2006 | US20060222715 Particles containing an acitve agent in the form of a co-precipitate |
| 10/05/2006 | US20060222714 Agent for preventing and ameliorating constipation |
| 10/05/2006 | US20060222713 Extended release pharmaceutical composition of phenytoin sodium |
| 10/05/2006 | US20060222712 Acne gel |
| 10/05/2006 | US20060222711 Composition of and method for preparing stable particles in a frozen aqueous matrix |
| 10/05/2006 | US20060222710 Composition of and method for preparing stable particles in a frozen aqueous matrix |
| 10/05/2006 | US20060222709 Metformin methods and formulations for treating chronic constipation |
| 10/05/2006 | US20060222708 Wafer comprising steroid hormones |
| 10/05/2006 | US20060222707 Formulations of fenofibrate |
| 10/05/2006 | US20060222706 Formulations of Fenofibrate |
| 10/05/2006 | US20060222703 Pharmaceutical composition and preparation method thereof |
| 10/05/2006 | US20060222699 Flavored vegetarian cellulose capsule and methods for producing said capsule. |
| 10/05/2006 | US20060222696 comprising one or more phosphatidylcholines, an N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-( omega )-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, cholesterol; cancer treatment |
| 10/05/2006 | US20060222694 Stabilized topotecan liposomal composition and methods |
| 10/05/2006 | US20060222692 Method and compositions for transdermal administration of antimicrobial medications |
| 10/05/2006 | US20060222691 Composition for the transdermal delivery of fentanyl |
| 10/05/2006 | US20060222690 Low-concentration capsaicin patch and methods for treating neuropathic pain |
| 10/05/2006 | US20060222689 vitamin C, vitamin B complex, carotene, vitamin E, a fragrance, a thickener and a surfactant; acne treamtent |
| 10/05/2006 | US20060222673 Injectable phosphatidylcholine preparations |
| 10/05/2006 | US20060222671 Dermatological compositions and salts for the treatment of dermatological diseases |
| 10/05/2006 | US20060222669 Use of tin (IV) mesoporphyrin IX dichloride in an aqueous solution having a physiological osmolarity for treatment of hyperbilirubinemia, elevated serum bilirubin concentration, jaundice; shelf life |
| 10/05/2006 | US20060222668 Stannsoporfin compositions, drug products and methods of manufacture |
| 10/05/2006 | US20060222655 Compositions and methods for preventing and treating endotoxin-related diseases and conditions |
| 10/05/2006 | US20060222649 Methods for inducing antigen-specific T cell tolerance |
| 10/05/2006 | US20060222640 New pharmaceutical compositions for treatment of thrombosis |
| 10/05/2006 | US20060222639 Wound treatment utilizing collagenase and a phosphotidylcholine organogel |